Skip to Content

DNA Print Genomics Inc DNAG

Morningstar Rating
$0.00 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

DNAG is trading at a 743% premium.
Price
$0.00
Fair Value
$5.49
Uncertainty
Extreme
1-Star Price
$9.73
5-Star Price
Economic Moat
Ymr
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DNAG is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.000.00
Bid/Ask
/
Market Cap
$644.61
Volume/Avg
11,770 / 182,890

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

DNA Print Genomics Inc is a pharmaceutical company that focuses on the human genome sciences. Through its subsidiaries, it is into research and development of genomic products and provides scientific services and tests to the genealogy, forensic, pharmaceutical, and genetics markets; and focuses on personalized medicine; and other operations.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
25
Website

Valuation

Metric
DNAG
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
DNAG
Quick Ratio
0.14
Current Ratio
0.17
Interest Coverage
Quick Ratio
No chart available

Profitability

Metric
DNAG
Return on Assets (Normalized)
−77.40%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
−13,021.99%
Return on Assets
No chart available
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
PvjrspmwlNff$636.2 Bil
Vertex Pharmaceuticals Inc
VRTX
HtmggwwXfdtkn$126.1 Bil
Regeneron Pharmaceuticals Inc
REGN
MvpnqhnxwRbpztf$121.2 Bil
Moderna Inc
MRNA
WkfpscrGjyh$46.5 Bil
Alnylam Pharmaceuticals Inc
ALNY
YzmwmwysgHgdcrgg$33.0 Bil
argenx SE ADR
ARGX
ZhqzjysTyx$27.9 Bil
BioNTech SE ADR
BNTX
WwrtpmpHlql$20.5 Bil
Biomarin Pharmaceutical Inc
BMRN
WcgkfsjLckfmr$16.1 Bil
United Therapeutics Corp
UTHR
XvxmtflqsRvx$14.3 Bil
Incyte Corp
INCY
HhywvrmymGnctxmf$12.5 Bil

Sponsor Center